Nkarta’s (NKTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Nkarta (NASDAQ:NKTX) in a research note published on Thursday morning,Benzinga reports. They currently have a $18.00 price objective on the stock. HC Wainwright also issued estimates for Nkarta’s Q4 2025 earnings at ($0.29) EPS and FY2029 earnings at ($0.99) EPS.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Nkarta in a research report on Thursday. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $14.86.

Nkarta Stock Up 1.5 %

NKTX stock opened at $2.00 on Thursday. Nkarta has a fifty-two week low of $1.31 and a fifty-two week high of $11.84. The business has a 50 day moving average price of $1.99 and a 200 day moving average price of $2.84. The stock has a market cap of $141.92 million, a price-to-earnings ratio of -1.06 and a beta of 0.90.

Nkarta (NASDAQ:NKTX) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. As a group, sell-side analysts anticipate that Nkarta will post -1.7 EPS for the current year.

Insider Buying and Selling

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the transaction, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. This trade represents a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 8.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Nkarta

Several institutional investors have recently modified their holdings of the company. Invesco Ltd. acquired a new position in Nkarta during the fourth quarter worth $30,000. Sequoia Financial Advisors LLC acquired a new position in shares of Nkarta during the 4th quarter worth $31,000. Erste Asset Management GmbH purchased a new stake in shares of Nkarta in the 3rd quarter worth about $33,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Nkarta in the 4th quarter worth about $37,000. Finally, ProShare Advisors LLC acquired a new stake in Nkarta in the 4th quarter valued at about $45,000. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.